查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951287

糞鈣衛蛋白檢測市場 - 全球產業規模、佔有率、趨勢、機會及預測（按檢測類型、適應症、最終用戶、地區和競爭格局分類，2021-2031年）

Fecal Calprotectin Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Assay Type, By Indication, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球糞便鈣衛蛋白檢測市場預計將從 2025 年的 3.531 億美元成長到 2031 年的 5.3021 億美元，複合年成長率為 7.01%。

這個市場的核心是非侵入性診斷免疫檢測，它透過測量糞便中存在的中性粒細胞蛋白質——鈣衛蛋白來識別腸道發炎。這項檢測主要用於區分嗜中性白血球(IBD) 和功能性胃腸疾病，例如大腸激躁症(IBS)。市場成長的主要促進因素是 IBD 盛行率的不斷上升，以及臨床上減少不必要的侵入性檢查（例如大腸鏡檢查）的趨勢，這些趨勢提高了患者的依從性並增強了成本效益。加拿大克隆氏症症和結腸炎協會估計，到 2025 年，發炎性腸道疾病在加拿大的盛行率將達到 0.8%，這凸顯了可靠疾病監測的必要性。

市場概覽
預測期 2027-2031
市場規模：2025年 3.531億美元
市場規模：2031年 5.3021億美元
複合年成長率：2026-2031年 7.01%
成長最快的細分市場 發炎性腸道疾病（IBD）
最大的市場 北美洲

然而，商業生產商之間檢測方法缺乏標準化，對市場擴張構成重大挑戰。不同檢測套組在分析性能和驗收基準值上的差異，常常導致結果不一致，使臨床醫生難以解讀數據，並阻礙了通用參考範圍的建立，而通用參考範圍對於患者照護至關重要。這種差異性造成了結果互換性的不確定性，並可能延緩檢測方法被接受為疾病活動監測金標準的進程。

市場促進因素

全球發炎性腸道疾病 (IBD) 盛行率的上升是推動全球糞鈣衛蛋白檢測市場成長的主要因素。克隆氏症和潰瘍性大腸炎等慢性疾病盛行率的增加，導致人們對可靠、非侵入性的監測工具的需求激增，這些工具能夠有效管理長期發炎並預防復發。根據美國疾病管制與預防中心 (CDC) 於 2024 年 6 月發布的《IBD 事實與統計》報告，美國 IBD 患者人數估計在 240 萬至 310 萬之間。不斷成長的患者群體需要頻繁進行檢測，以區分活動性發炎和功能性疾病，這推動了對鈣衛蛋白檢測的需求成長。國際上也出現了類似的趨勢：根據英國克隆氏症症和結腸炎協會 2024 年的報告，英國約有 50 萬人患有 IBD，這凸顯了可擴展診斷解決方案的必要性。

隨著這項需求的成長，居家檢測和照護現場盒的技術進步正透過提高檢體穩定性和提升患者便利性來改變市場格局。儘管糞便檢體在運輸過程中保存的物流挑戰歷來阻礙了遠端監測的廣泛應用，但緩衝液穩定性的最新改進正在逐步解決這些障礙。例如，Sentinel Diagnostics公司於2024年11月宣布，其CALiAGold Pierce Tubes試管新增一項功能，可讓患者在分析前將檢體在室溫下保存長達四周。此類創新透過簡化檢體採集流程、促進在臨床環境之外進行持續的疾病監測以及加速需要終身管理的患者的市場滲透，顯著提高了患者的依從性。

市場挑戰

商業廠商之間缺乏標準化的檢測方法是全球糞便鈣衛蛋白檢測市場成長的主要障礙。不同的檢測套組通常採用不同的抗體和捕獲方法，導致同一患者檢體的定量結果和臨界值有差異。這種分析變異性使臨床解讀變得複雜，醫療機構難以確定通用的參考範圍，也難以比較不同檢測平台的數據。因此，臨床醫生仍不願完全依賴這些免疫檢測進行患者後續觀察，阻礙了該診斷工具在常規醫療實踐中的廣泛應用。

這種不一致直接阻礙了市場擴充性的擴大，尤其是在對可靠的慢性病管理需求龐大的情況下。根據克隆氏症和結腸炎基金會2024年的預測，約有300萬美國人患有發炎性腸道疾病，這是一個龐大的患者群體，需要頻繁進行發炎監測。然而，不同製造商之間檢測結果無法協調一致，造成了營運瓶頸。如果檢測數據無法在不同檢查室間互通，醫療系統不太可能全面採用這些檢測方法，從而限制了這些診斷產品的收入潛力和整體市場滲透率。

市場趨勢

隨著臨床檢查室從手動方法轉向整合平台以應對日益成長的檢體量，市場正經歷著向自動化高通量檢查室免疫檢測的轉變。傳統的酵素免疫分析法(ELISA) 正被可在標準臨床化學分析儀上運行的顆粒增強濁度免疫檢測(PETIA) 所取代，從而實現隨機訪問檢測並顯著縮短結果週轉時間。這種自動化使診斷機構能夠有效地擴展業務規模，以滿足不斷成長的胃腸道檢測需求。例如，Sysmex America 於 2025 年 1 月宣布與加拿大達成 Sentinel Diagnostics SENTiFIT 800 分析儀的經銷協議。這款高速系統每小時可處理多達 550 個檢體，從而實現大通量檢體分析。

同時，市場正在拓展其在「縱向治療監測」和「黏膜癒合評估」方面的應用，超越了此檢測最初區分發炎性腸道疾病（IBD）和腸躁症（IBS）的功能。臨床醫生正在採用「目標導向治療」策略，利用頻繁的糞鈣衛蛋白檢測作為一種非侵入性手段，取代內視鏡檢查，以評估已確診患者的治療反應和黏膜發炎情況。這種臨床轉變得益於旨在支持定期疾病後續觀察的醫保報銷體系的不斷發展。例如，《邊緣系統》（The Limbic）在2025年10月報道稱，澳洲政府推出了一項新的醫療保險項目編號，用於支持在已確診炎症性腸病（IBD）症狀患者的持續管理中進行鈣衛蛋白檢測，這反映了全球對該檢測在長期護理中價值的認可。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球糞便鈣衛蛋白檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依檢測類型（酵素免疫分析法（ELISA）、酵素螢光免疫分析、定量層析法）
    • 依適應症（發炎性腸道疾病 (IBD) 診斷、結腸癌、乳糜瀉、其他）
    • 依最終使用者（醫院、診斷檢查室、學術研究機構等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美糞便鈣衛蛋白檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲糞便鈣衛蛋白檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區糞便鈣衛蛋白檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲糞便鈣衛蛋白檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲糞便鈣衛蛋白檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球糞鈣衛蛋白檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Boditech Med Inc.
  • Abbexa Ltd.
  • Elabscience Bionovation Inc.
  • Epitope Diagnostics, Inc.
  • R-Biopharm AG
  • Sentinel Ch SpA
  • LifeSpan BioSciences, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24527

The Global Fecal Calprotectin Test Market is projected to increase from USD 353.10 Million in 2025 to USD 530.21 Million by 2031, expanding at a CAGR of 7.01%. This market centers on a non-invasive diagnostic immunoassay that measures calprotectin, a neutrophilic protein present in stool, to identify intestinal inflammation. The test is primarily employed to distinguish between Inflammatory Bowel Disease (IBD) and functional gastrointestinal disorders like Irritable Bowel Syndrome (IBS). Growth is largely driven by the rising prevalence of IBD and a clinical shift toward reducing unnecessary invasive procedures, such as colonoscopies, which improves patient compliance and cost-efficiency. Underscoring the need for reliable disease monitoring, Crohn's and Colitis Canada estimates that the prevalence of Inflammatory Bowel Disease will reach 0.8% of the Canadian population in 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 353.10 Million
Market Size 2031USD 530.21 Million
CAGR 2026-20317.01%
Fastest Growing SegmentInflammatory Bowel Disease (IBD)
Largest MarketNorth America

However, the lack of assay standardization across commercial manufacturers presents a significant challenge to broader market expansion. Differences in analytical performance and cut-off values among various test kits often result in inconsistent findings, complicating data interpretation for clinicians and preventing the creation of universal reference ranges essential for long-term patient care. This variability generates uncertainty regarding the interchangeability of results, potentially delaying the acceptance of these tests as the primary standard for monitoring disease activity.

Market Driver

The rising global incidence of Inflammatory Bowel Diseases (IBD) acts as a primary catalyst for the growth of the Global Fecal Calprotectin Test Market. As chronic conditions like Crohn's disease and ulcerative colitis become more widespread, there is a surging demand for reliable, non-invasive monitoring tools to effectively manage long-term inflammation and prevent relapses. The Centers for Disease Control and Prevention's 'IBD Facts and Stats' report from June 2024 estimated that between 2.4 and 3.1 million individuals in the United States have IBD. This growing patient population requires frequent testing to differentiate active inflammation from functional disorders, thereby fueling the consumption of calprotectin assays. This trend is further supported internationally, with Crohn's & Colitis UK reporting in 2024 that approximately 500,000 people in the United Kingdom live with IBD, highlighting the need for scalable diagnostic solutions.

Concurrent with this demand, technological advancements in home-testing and point-of-care kits are reshaping the market by improving sample stability and patient convenience. Historically, logistical difficulties in preserving fecal samples during transport hindered the adoption of remote monitoring, but recent improvements in buffer stability have addressed these barriers. For example, Sentinel Diagnostics announced in November 2024 the capabilities of its new CALiaGold pierce Tube, which allows patients to store samples at room temperature for up to four weeks before analysis. Such innovations significantly enhance compliance by simplifying the collection process, facilitating consistent disease monitoring outside clinical settings, and accelerating market penetration for patients requiring lifelong management.

Market Challenge

The absence of assay standardization among commercial manufacturers constitutes a major barrier to the Global Fecal Calprotectin Test Market's growth. Because different test kits frequently employ distinct antibodies and capture methods, they often yield inconsistent quantitative results and cut-off values for identical patient samples. This analytical variability complicates clinical interpretation, making it challenging for healthcare providers to define universal reference ranges or compare data across different testing platforms. Consequently, clinicians remain hesitant to rely exclusively on these immunoassays for longitudinal patient monitoring, which limits the widespread integration of this diagnostic tool into routine medical practice.

This inconsistency directly impedes market scalability, particularly given the critical demand for reliable chronic disease management. With the Crohn's & Colitis Foundation estimating in 2024 that approximately 3 million Americans are affected by Inflammatory Bowel Disease, a substantial patient population requires frequent inflammation monitoring. However, the inability to harmonize results across different manufacturers creates an operational bottleneck. Healthcare systems are unlikely to fully commit to a testing modality where data cannot be interchanged between laboratories, thereby restricting the revenue potential and overall market penetration of these diagnostic products.

Market Trends

The market is being transformed by a shift toward Automated High-Throughput Laboratory Immunoassays as clinical laboratories move from manual methods to integrated platforms to manage increasing sample volumes. Traditional Enzyme-Linked Immunosorbent Assays (ELISA) are being replaced by particle-enhanced turbidimetric immunoassays (PETIA) that operate on standard clinical chemistry analyzers, allowing for random-access testing and significantly reduced turnaround times. This automation enables diagnostic facilities to scale operations efficiently to meet the rising demand for gastrointestinal testing. Illustrating this advancement, Sysmex America announced in January 2025 an agreement to distribute the Sentinel Diagnostics SENTiFIT 800 Analyzer in Canada, a high-speed system capable of processing up to 550 tests per hour to handle mass-volume analysis.

Simultaneously, the market is seeing increasing utilization for Longitudinal Treatment Monitoring and Mucosal Healing, expanding beyond the test's original role of distinguishing IBD from IBS. Clinicians are adopting "treat-to-target" strategies that use frequent fecal calprotectin measurements as a non-invasive surrogate for endoscopy to assess therapeutic response and mucosal inflammation in established patients. This clinical shift is validated by evolving reimbursement structures aimed at supporting regular disease tracking. For instance, The Limbic reported in October 2025 that the Australian government introduced a new Medicare item number to subsidize calprotectin testing for the ongoing management of symptomatic patients with an established IBD diagnosis, reflecting global recognition of the test's value in long-term care.

Key Market Players

  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Boditech Med Inc.
  • Abbexa Ltd.
  • Elabscience Bionovation Inc.
  • Epitope Diagnostics, Inc.
  • R-Biopharm AG
  • Sentinel Ch S.p.A.
  • LifeSpan BioSciences, Inc

Report Scope

In this report, the Global Fecal Calprotectin Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fecal Calprotectin Test Market, By Assay Type

  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Enzyme Fluoroimmunoassay
  • Quantitative Immune-Chromatography

Fecal Calprotectin Test Market, By Indication

  • Inflammatory Bowel Disease (IBD) Diagnosis
  • Colorectal Cancer
  • Celiac Disease
  • others

Fecal Calprotectin Test Market, By End User

  • Hospitals
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • others

Fecal Calprotectin Test Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fecal Calprotectin Test Market.

Available Customizations:

Global Fecal Calprotectin Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fecal Calprotectin Test Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Assay Type (Enzyme Linked Immunosorbent Assay (ELISA), Enzyme Fluoroimmunoassay, Quantitative Immune-Chromatography)
    • 5.2.2. By Indication (Inflammatory Bowel Disease (IBD) Diagnosis, Colorectal Cancer, Celiac Disease, others)
    • 5.2.3. By End User (Hospitals, Diagnostic Laboratories, Academic and Research Institutes, others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Fecal Calprotectin Test Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Assay Type
    • 6.2.2. By Indication
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Fecal Calprotectin Test Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Assay Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Fecal Calprotectin Test Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Assay Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Fecal Calprotectin Test Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Assay Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End User

7. Europe Fecal Calprotectin Test Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Assay Type
    • 7.2.2. By Indication
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Fecal Calprotectin Test Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Assay Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End User
    • 7.3.2. France Fecal Calprotectin Test Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Assay Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Fecal Calprotectin Test Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Assay Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Fecal Calprotectin Test Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Assay Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Fecal Calprotectin Test Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Assay Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By End User

8. Asia Pacific Fecal Calprotectin Test Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Assay Type
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Fecal Calprotectin Test Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Assay Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. India Fecal Calprotectin Test Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Assay Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Fecal Calprotectin Test Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Assay Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Fecal Calprotectin Test Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Assay Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Fecal Calprotectin Test Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Assay Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End User

9. Middle East & Africa Fecal Calprotectin Test Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Assay Type
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Fecal Calprotectin Test Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Assay Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Fecal Calprotectin Test Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Assay Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Fecal Calprotectin Test Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Assay Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End User

10. South America Fecal Calprotectin Test Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Assay Type
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Fecal Calprotectin Test Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Assay Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Fecal Calprotectin Test Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Assay Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Fecal Calprotectin Test Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Assay Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Fecal Calprotectin Test Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Rad Laboratories, Inc.
  • 15.3. F. Hoffmann-La Roche Ltd
  • 15.4. Boditech Med Inc.
  • 15.5. Abbexa Ltd.
  • 15.6. Elabscience Bionovation Inc.
  • 15.7. Epitope Diagnostics, Inc.
  • 15.8. R-Biopharm AG
  • 15.9. Sentinel Ch S.p.A.
  • 15.10. LifeSpan BioSciences, Inc

16. Strategic Recommendations

17. About Us & Disclaimer